about
Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.The acceptability and feasibility of a brief psychosocial intervention to reduce blood-borne virus risk behaviours among people who inject drugs: a randomised control feasibility trial of a psychosocial intervention (the PROTECT study) versus treatmAssociation between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs.Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs.Engagement in a National Naloxone Programme among people who inject drugs.Preventing blood-borne virus infection in people who inject drugs in the UK: systematic review, stakeholder interviews, psychosocial intervention development and feasibility randomised controlled trial.Correction to: Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study.Spore forming bacteria infections and people who inject drugs: Implications for harm reduction.Psychiatric comorbidity and intimate partner violence among women who inject drugs in Europe: a cross-sectional study.Prison-based prescriptions aid Scotland's National Naloxone Programme.Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland"Once I'd done it once it was like writing your name": Lived experience of take-home naloxone administration by people who inject drugsEmergence of Novel Psychoactive Substance injecting associated with rapid rise in the population prevalence of hepatitis C virusRe-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis
P50
Q33769960-2F823FD2-DE16-412F-8BA0-CB4C8359EF9DQ34028058-40813712-61D5-4813-A4C6-272600FF859AQ37713321-80867542-234B-4518-87B1-9A29CD0AD3B3Q38677838-FCC610C3-3F91-4FEC-A3F2-4A2573058302Q38893360-DC99AE60-CFFF-4F56-92F8-B53A97B9B30AQ39930793-DDA4E2DE-A135-414B-BFD9-14D5987E8D02Q45323764-DD5D7EE5-7C0B-4485-B36A-E95AA2629BF1Q47558541-EA619296-95F8-49BE-AC41-DD15A855F2E7Q47562018-CBC8073F-CE4F-4C7D-A320-1DB043258B78Q47577981-1799661C-5D36-489C-970D-F699B6231583Q47930896-F4D43030-CF94-41B2-A588-BC1A7EFE75EFQ50135239-70A2DD70-7412-4316-95DE-0B1179D22621Q57700820-85B08E41-7CE2-41C9-B03D-28036010BCA8Q88870413-FAE9592A-46C9-476A-8670-30A00C3E8F82Q91251633-35825D60-203B-4DE1-8FF5-072A913123D3Q93075279-119A6F96-963C-4771-A512-49147925EE75
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Alison Munro
@en
Alison Munro
@nl
type
label
Alison Munro
@en
Alison Munro
@nl
prefLabel
Alison Munro
@en
Alison Munro
@nl
P31
P496
0000-0002-2350-8128